Related Experiment Video
Updated: Aug 14, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Interferon-alpha as maintenance therapy in patients with multiple myeloma
C G Schaar1, H C Kluin-Nelemans, C Te Marvelde
1Department of Internal Medicine, Gelre Hospitals, Apeldoorn, The Netherlands. c.schaar@gelre.nl
Interferon-alpha 2b (IFN-alpha-2b) maintenance therapy for multiple myeloma (MM) significantly improves progression-free survival. While it does not enhance overall survival, it maintains quality of life when toxicity is managed.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Investigated the impact of interferon-alpha 2b (IFN-alpha-2b) on elderly multiple myeloma (MM) patients post-melphalan/prednisone induction.
- Focused on patients who achieved a plateau phase, assessing effects on survival and quality of life (QoL).
Purpose of the Study:
- To evaluate the efficacy of IFN-alpha-2b as maintenance therapy in MM.
- To determine its effect on progression-free survival (PFS), overall survival (OS), and QoL.
Main Methods:
- An open-label Phase III trial involving 262 MM patients (median age 69).
- 128 patients reached plateau phase; 90 were randomized to IFN-alpha-2b or no maintenance therapy.
- Reasons for non-randomization included refusal, comorbidities, and performance status.
Main Results:
- IFN-alpha-2b maintenance therapy showed improved PFS (13.5 vs. 8.4 months from randomization).
- No significant improvement in overall survival was observed (41 vs. 38.4 months).
- One-third of patients discontinued IFN-alpha due to toxicity; QoL remained comparable between groups.
Conclusions:
- IFN maintenance therapy in MM prolongs progression-free survival.
- It does not adversely affect QoL if toxicity is managed effectively.
- The study highlights a benefit in PFS without a significant OS improvement in this patient group.
More Related Videos
10:10Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Inhibitors of Viral Protein Synthesis